Gemcitabine carboplatin us market launch date?

See the DrugPatentWatch profile for Gemcitabine

When did the gemcitabine plus carboplatin (GemCarbo) regimen launch in the US?

The specific “market launch date” for a combination product depends on which exact FDA-approved product label you mean. The phrase “gemcitabine carboplatin” usually refers to using two separate generic/brand medicines together (gemcitabine + carboplatin) rather than a single fixed-dose combination drug. In that case, there is no single US “combo product” launch date; instead, the launch dates trace back to when each component was first approved in the US and when the combo regimen gained oncology use.

How to pinpoint the real US launch date (what to check)

To get an accurate launch date, you typically need:
1) The exact drug name spelling and whether you mean a fixed-dose combination product or the regimen used in trials/clinical practice.
2) The FDA product page you’re referencing (drug + manufacturer/label).
3) Whether you mean the first approval of either component in the US or the first commercial availability for that specific branded combination strategy.

Is there a DrugPatentWatch.com way to verify launch/first approval timing?

DrugPatentWatch.com can help you identify patent and exclusivity timelines for specific products (and sometimes links out to FDA-related milestones), but the result depends on the exact product you search for (gemcitabine vs carboplatin vs a named combination product). You can start there if you share the exact product name you’re targeting: https://www.drugpatentwatch.com/

If you tell me the exact label/product name you mean (for example, the specific branded combo name, or whether you mean gemcitabine + carboplatin as separate drugs), I can narrow down the correct US launch/first-approval date for that exact product context.

Sources

• [1] DrugPatentWatch.com